• Monthly
    Established in 1973

    Responsible Institution
    Health Commission of Hubei Province
    Hubei Cancer Hospital
    Chinese Anti-Cancer Association
    Editorial Board of Cancer Research on Prevention and Treatment
    Wei Shaozhong

    ISSN 1000-8578
    CN 42-1241/R
    Subscription Code 38-70
    Code: MO6482
    Add:116 Zhuodaoquan South Road, Hongshan District,Wuhan 430079,China
    Price: RMB 20.00

Current Issue

, Volume 49 Issue 03 Previous Issue    Next Issue
For Selected: View Abstracts Toggle Thumbnails
Research Progress of Etiology, Screening and Early Diagnosis of Esophageal Cancer in China
YANG Huan, SUN Wanyi, WANG Jianbing, WANG Xiaokun, ZHANG Jinyu, FAN Jinhu, QIAO Youlin
Cancer Research on Prevention and Treatment. 2022, 49 (03): 169-175.   DOI: 10.3971/j.issn.1000-8578.2022.21.1033
Abstract( 1029 PDF (4391KB)  ( 125 ) )   HTML ()
Esophageal cancer (EC) is one of the most fatal cancers worldwide. According to GLOBOCAN 2020, it was estimated that there were 600,000 new EC cases and 540 000 EC deaths, while nearly half of all newly diagnosed cases of EC and associated deaths worldwide occurred in China. The annual incidence and mortality of EC have been reduced in the last 20 years in China. However, the early symptoms and signs of EC are not easily distinguished and the disease tends to be within the middle and late stage of pathogenesis when identified, leading to its low 5-year survival rate. Therefore, it could help effectively reduce the burden of EC by clarifying its etiology and risk factors, as well as taking preventive and early diagnosis measures. This article reviews the epidemiology, etiology, screening and early diagnosis of EC in China, to provide systematic references for EC prevention and control.
Review of Development of Emerging Clinical Antitumor Therapeutics
ZHANG Wenqing, WU Jing, XIE Di, SHI Xuecong, HU Hankun
Cancer Research on Prevention and Treatment. 2022, 49 (03): 176-181.   DOI: 10.3971/j.issn.1000-8578.2022.21.1034
Abstract( 160 PDF (3817KB)  ( 178 ) )   HTML ()
Abstract: With the continuous progress of tumor treatment methods in recent years, more and more emerging antitumor drugs have been approved to market and put into clinical use. In addition, some treatments that are in clinical trials such as gene therapy are also continuously making new breakthroughs. In this review, we mainly give a brief introduction to the novel antineoplastic therapies that have been clinically used in recent years, as well as the ones with remarkable efficacy and are expected to be approved for marketing.
Inhibitory Effect of Loropetalum Chinense on Proliferation of Lung Adenocarcinoma A549 Cells
XIA Qisheng, DENG Tingting, XU Yaping, LIU Honglin, LIU Haoyuan
Cancer Research on Prevention and Treatment. 2022, 49 (03): 182-186.   DOI: 10.3971/j.issn.1000-8578.2022.21.0708
Abstract( 159 PDF (4845KB)  ( 50 ) )   HTML ()
Objective To investigate the effects of Loropetalum chinense extracts on the proliferation of lung adenocarcinoma A549 cells cultured in vitro. Methods CCK-8 assay was performed to evaluate the effect of Loropetalum chinense extracts on the proliferation of A549 cells, and the clonal growth ability of A549 cells was determined by clone formation assay. Flow cytometry Annexin V-APC/PI double staining was used to measure the apoptosis of A549 cells. Western blot was used to measure the expressions of apoptosisrelated proteins Bax, Fas, Bcl-2 Caspase3 and cleaved-Caspase 3. Results Loropetalum chinense extracts significantly inhibited the proliferation and colony formation of A549 cells in a time- and dose-dependent manner. The viability of A549 cells decreased by 50% after 48h treatment of 0.5mg/ml extracts, and 100% inhibition of colony formation rate achieved when the cells were treated with 40μg/ml extracts for 14 days. When A549 cells were treated with Loropetalum chinense extracts for 24h, apoptotic rates increased in a dosedependent manner. Compared with the control group, the protein levels of Fas, Bax, Caspase3 and cleaved- Caspase3 were up-regulated, while Bcl-2 was down-regulated. Conclusion Loropetalum chinense extracts inhibit the growth of human lung adenocarcinoma cells in vitro, and the mechanisms may be related to the activation of mitochondrial and death receptor apoptosis pathway.
IFN-γ Inhibits Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Downregulating CXCL8 Expression
CHEN Huicong, LIU Yunjiang, ZHAO Jidong, CAO Miao, LI Xinhui, REN Shuguang, ZHANG Xiangmei, SHAN Baoen
Cancer Research on Prevention and Treatment. 2022, 49 (03): 187-191.   DOI: 10.3971/j.issn.1000-8578.2022.21.0901
Abstract( 155 PDF (7020KB)  ( 53 ) )   HTML ()
Objective To investigate the effect of IFN-γ on the proliferation and migration of esophageal squamous cell carcinoma cell line Eca9706 and related mechanism. Methods Cells were cultured in vitro and treated with interferon-γ. Cell morphology changes were observed under microscope, cell proliferation ability was detected by CCK-8 experiment, and cell migration ability was detected by cell scratch experiment and Transwell experiment. Real-time PCR method was used to detect the expression efficiency of chemokine CXCL8 (interleukin 8), and the ELISA experiment was used to detect the change of CXCL8 secretion. Results Compared with the blank control group, Eca9706 cells treated with different concentrations of interferon-γ did not change significantly in cell morphology. CCK8 experiment confirmed that the proliferation ability of Eca9706 cells after IFN-γ treatment was significantly reduced (P<0.01). Cell scratch experiment found that IFN-γ significantly decreased the migration ability of Eca9706 cells (P<0.01). Transwell experiment showed that after IFN-γ treatment, the migration ability of Eca9706 cells was significantly inhibited (P<0.01). CXCL8 gene expression level in Eca9706 cells treated with interferon-γ was significantly down-regulated (P<0.01), and the amount of CXCL8 secretion significantly reduced (P<0.05). Conclusion Interferon-γ can inhibit the proliferation and migration of esophageal cancer cell line Eca9706, which may be related to its inhibition of the expression and secretion of CXCL8.
Effect of PTENP1 on Proliferation and Apoptosis of Colorectal Cancer Cells and Its Molecular Mechanism
HU Xiaoshu, WEN Yiyang, YANG Jinhua
Cancer Research on Prevention and Treatment. 2022, 49 (03): 192-196.   DOI: 10.3971/j.issn.1000-8578.2022.21.0819
Abstract( 147 PDF (3915KB)  ( 93 ) )   HTML ()
Objective To investigate the effect of PTENP1 on the proliferation and apoptosis of colorectal cancer cells and its molecular mechanism. Methods We selected 107 cases of colorectal cancer and corresponding adjacent tissues as the research objects. The expression level of PTENP1 was analyzed by fluorescence quantitative PCR. Colon cancer HT29 cells with PTENP1 overexpression (PTENP1 group) and empty vector cell line (control group) were established by lentivirus. The cell proliferation and apoptosis were analyzed by CCK8 and flow cytometry. The PTENP1 target gene was analyzed by bioinformatics and double luciferase reporter genes. The expression level of target protein was analyzed by Western blot. Results The expression of PTENP1 in colorectal cancer tissues was significantly lower than that in adjacent tissues (P<0.05). The expression level of PTENP1 in the control group was significantly lower than that in the PTENP1 group (P<0.05). Compared with the control group, the cell proliferation ability of the PTENP1 group was significantly decreased (P<0.05), the apoptosis level was significantly increased (P<0.05). miR-21 was complementary to PTENP1. Compared with the control group, the expression of miR-21 in the PTENP1 group was significantly down-regulated (P<0.05), and the expression of PTEN protein was significantly upregulated (P<0.05). Conclusion PTENP1 and miR-21 competitively bind to regulate the expression of PTEN, and then affect the proliferation and apoptosis of colorectal cancer cells.
Construction and Validation of A Nomogram Prognostic Model for Patients with Lung Adenocarcinoma
LUO Wenqing, LI Yuanqi, YE Fei, LI Qiangming, ZHANG Guoqing, LI Xiangnan
Cancer Research on Prevention and Treatment. 2022, 49 (03): 197-204.   DOI: 10.3971/j.issn.1000-8578.2022.21.0623
Abstract( 194 PDF (5263KB)  ( 82 ) )   HTML ()
Objective To construct a nomogram prognostic model for predicting the survival of patients with lung adenocarcinoma based on the large sample data from the SEER database. Methods We retrospectively analyzed the clinical data of patients who were diagnosed with lung adenocarcinoma from 2010 to 2015 in the SEER database. A nomogram model was created based on independent parameters influencing the prognosis of patients with lung adenocarcinoma using Lasso Cox regression analysis. The C-index and calibration curve were utilized to assess the ability to distinguish and calibrate the nomogram. NRI and DCA curves were used to evaluate the prediction ability and net benefit of the nomogram. Results A total of 15 independent risk factors affecting the prognosis of lung adenocarcinoma were identified and integrated into the nomogram model. The C-index of the prediction model was 0.819 in the training cohort and 0.810 in the validation cohort. The predicted specific survival rate of the 1-, 3- and 5-year calibration curves of the training cohort and the validation cohort were consistent with the actual specific survival rate. In comparison to the 7th edition of the AJCC TNM staging system, the NRI and DCA curves demonstrated a considerable boost to the predictive capacity and net benefits achieved by the nomogram model. The risk stratification model constructed with this nomogram model was able to distinguish the patients with different risks well (P<0.0001). Conclusion A nomogram prognostic model is successfully developed and validated, which provides asimple and reliable tool for the survival prediction of the patients with lung adenocarcinoma. Meanwhile, therisk stratification model constructed by the prediction model can conveniently screen patients with different risks, which is important for the individualized treatment of lung adenocarcinoma patients.
Effects of Chemoradiotherapy Versus Chemotherapy Alone on Survival of Patients with Primary Mediastinal Large B-cell Lymphoma
FAN Bingjie, CHANG Yu, LIU Xiyang, ZHANG Mingzhi, ZHANG Lei
Cancer Research on Prevention and Treatment. 2022, 49 (03): 205-212.   DOI: 10.3971/j.issn.1000-8578.2022.21.0716
Abstract( 165 PDF (6018KB)  ( 47 ) )   HTML ()
Objective To explore the prognostic factors of primary mediastinal large B-cell lymphoma (PMBCL) and the effects of chemoradiotherapy versus chemotherapy alone on patients’ prognosis before and after rituximab era. Methods We extracted the data of PMBCL patients diagnosed from 2001 to 2015 from SEER database. SEER Stat software was used to calculate the incidence rate. Kaplan-Meier method and Cox regression model were used to analyze the impact of various clinical variables on prognosis. Results We included 635 patients with PMBCL. Multivariate Cox regression analysis showed that age, stage and chemotherapy were independent prognostic factors. Kaplan-Meier survival analysis showed that OS of the patients receiving chemotherapy only in 2006-2015 was significantly better than that in 2001-2005 (χ 2=10.002, P=0.002). The patients who received chemoradiotherapy had better OS than those who received chemotherapy alone from 2001 to 2005. The OS and DSS of patients receiving chemoradiotherapy were not significantly different from those of chemotherapy alone from 2006 to 2015. Conclusion The application of rituximab improves the long-term survival of PMBCL patients. The prognosis of patients who received chemoradiotherapy is comparable to that of chemotherapy alone from 2006 to 2015.
Clinical Value of Platelet and Its Parameters Combined with Tumor Markers in Preoperative Differentiation of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
ZHANG Haodong, WEI Fengxian, ZHANG Chunfang, XU Xiaodong
Cancer Research on Prevention and Treatment. 2022, 49 (03): 213-218.   DOI: 10.3971/j.issn.1000-8578.2022.21.0898
Abstract( 133 PDF (3659KB)  ( 33 ) )   HTML ()
Objective To evaluate the value of PLT and its parameters combined with AFP, CA199, CA125 and CEA on the preoperative differential diagnosis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Methods We analyzed retrospectively 274 patients with liver cancer who underwent surgery in the Second Hospital of Lanzhou University. They were divided into 229 cases in HCC group and 45 cases in ICC group according to postoperative pathological results. The differences of PLT, its parameters and tumor markers between the two groups were compared. ROC curve was used to evaluate the differential diagnosis effect on HCC and ICC by significantly different indicators in single and combined forms. The best scheme was verified in the patients with determined and undetermined preoperative diagnosis. Results Compared with HCC group, the levels of PLT, PCT, CA199 and CA125 in ICC group were higher (P<0.05) and the level of AFP was lower (P<0.05). The diagnostic analysis results of ROC curve showed that in single test, the AUC of AFP for HCC diagnosis was the largest (0.827). The AUC of the combined groups was higher than the single groups of tumor markers; the AUC of the PCT+AFP+CA199+CA125 group was the highest in all combination groups, and AUC was 0.891. The verification of the best combination group showed that the AUC was 0.924 in the preoperative determined diagnosis group and 0.854 in the undetermined diagnosis group. Conclusion Tumor markers in combination with PLT and PCT can increase the preoperative differential diagnosis efficacy of HCC and ICC. The combination of PCT, AFP, CA199 and CA125 before operation is helpful to further determine the diagnosis and plan the operation scheme.
Efficacy and Safety of Apatinib Monotherapy as Subsequent-line Therapy on Patients with Advanced Esophageal Squamous Cell Carcinoma
HOU Jiyuan, QI Peihong, WANG Haixia, GONG Zhe, SHAN Guoyong
Cancer Research on Prevention and Treatment. 2022, 49 (03): 219-224.   DOI: 10.3971/j.issn.1000-8578.2022.21.0742
Abstract( 144 PDF (3397KB)  ( 31 ) )   HTML ()
Objective To investigate the efficacy and safety of apatinib monotherapy as subsequent-line therapy on patients with advanced ESCC. Methods We included 56 patients with advanced ESCC who were administered with apatinib monotherapy. The initial dosage of apatinib was 500mg or 250mg daily. Clinicopathological characteristics, adverse reaction and prognosis of the patients were analyzed. The primary endpoint of this study was PFS, the secondary endpoints were ORR, DCR, OS and safety of apatinib administration. Results All the 56 patients with ESCC corresponded with the eligibility criteria and were available for the evaluation of efficacy and adverse reaction. The ORR of the 56 patients who received apatinib monotherapy was 8.9% (95%CI: 3.0%-19.6%) and DCR was 64.3% (95%CI: 50.4%-76.6%). The median PFS was 3.7 months (95%CI: 3.19-4.21) and the median OS was 6.3 months (95%CI: 3.53-9.08). The common adverse reactions were hypertension (50.0%), fatigue (41.1%), loss of appetite (35.7%), hand-foot syndrome (30.4%) and diarrhea (26.8%). Conclusion Apatinib monotherapy demonstrates potential efficacy and tolerable safety as the further-line treatment for the patients with advanced ESCC. And the conclusion should be validated in prospective clinical studies subsequently.
Research Progress of PD-L1 Expression in Circulating Tumor Cells in Malignant Tumors
LI Zuxi, HUANG Xianbin, MA Yuntao, ZHAN Weipeng, HU Ming, TIAN Hongwei, YANG Jing,
Cancer Research on Prevention and Treatment. 2022, 49 (03): 225-229.   DOI: 10.3971/j.issn.1000-8578.2022.21.0648
Abstract( 195 PDF (4120KB)  ( 78 ) )   HTML ()
In recent years, with the in-depth study of PD-1 and PD-L1 and the development of immunotherapy, the first problem is how to screen the beneficiaries. Recent clinical studies have shown that the expression level of PD-L1 in circulating tumor cells (CTC) can be used as a potential biomarker to play a guiding role in immunotherapy of malignant tumors. This article reviews the latest clinical research progress on the expression of PD-L1 in circulating tumor cells in various solid tumors.
Role and Mechanism of BDH2 Gene in Metabolism, Tumorigenesis and Progression of Cancer
LIU Bingchun, LI Kang, YUAN Jianlong
Cancer Research on Prevention and Treatment. 2022, 49 (03): 230-234.   DOI: 10.3971/j.issn.1000-8578.2022.21.0995
Abstract( 153 PDF (2960KB)  ( 54 ) )   HTML ()
Cellular metabolism in tumor is an important biological process to promote the occurrence and development of tumor, and the genes related to cellular metabolism are gradually becoming the targets of tumor treatment. However, more researches are still needed to explore the abnormal metabolism in tumor progression and its prognostic value. BDH2 gene is a multifunctional gene, participates in a variety of metabolic pathways, plays an important catalytic role in iron metabolism, participates in ketone metabolism and is related to lipid metabolism. In recent years, researchers have found that BDH2 plays distinct roles in various types of tumors. The occurrence and development of a variety of tumors are closely related to BDH2. This paper analyzes, summarizes and prospects the role and mechanism of BDH2 in metabolism and tumorigenesis.
Advances in Neoadjuvant Therapy for Locally Advanced Rectal Cancer
JIANG Yujuan, ZHOU Sicheng, PEI Wei, LIANG Jianwei, ZHOU Zhixiang
Cancer Research on Prevention and Treatment. 2022, 49 (03): 235-239.   DOI: 10.3971/j.issn.1000-8578.2022.21.0783
Abstract( 146 PDF (2949KB)  ( 68 ) )   HTML ()
The treatment of locally advanced rectal cancer (LARC) is extremely challenging, and it is difficult to achieve satisfactory results with surgical resection alone. In recent years, the diagnosis and treatment of LARC tends to be multi-disciplinary (MDT) mode. The emerging neoadjuvant treatment strategy is a milestone. At present, the preferred treatment for LARC is neoadjuvant chemoradiotherapy combined with total mesorectal excision. This article summarizes the main treatments of LARC neoadjuvant therapy, hoping to provide reference for clinical diagnosis and treatment.
Research Progress of Exosome-based Liquid Biopsy in Diagnosis of Pancreatic Cancer
GUO Madi, ZHAO Juan, HUANG Xiaoyi
Cancer Research on Prevention and Treatment. 2022, 49 (03): 240-245.   DOI: 10.3971/j.issn.1000-8578.2022.21.1008
Abstract( 140 PDF (2993KB)  ( 40 ) )   HTML ()
Pancreatic cancer (PC) is a highly malignant tumor of the digestive system. Due to the lack of sensitive and effective detection markers, the tumor is usually at a relatively advanced stage in initial diagnosis. Therefore, early detection of PC is crucial for timely treatment and better prognosis. Exosomes are extracellular vesicles secreted by cells. They have a lipid bimolecular membrane structure to ensure the stable existence of a large number of biologically active substances contained therein. So they can accurately reflect the characteristics of parental cells. Exosomes are widely present in various body fluids and can noninvasively, conveniently and real-timely extracted, with the potential to become a marker for early tumor diagnosis. Previous studies have shown that compared with traditional diagnostic methods, exosomes showed higher sensitivity and specificity in the early diagnosis of various cancers. This article reviews the research progress of exosomes in the early diagnosis of pancreatic cancer.
Diffuse Malignant Peritoneal Mesothelioma with Paraneoplastic Syndrome: A Case Report and Literature Review
SU Yandong, LIU Gang, DU Xuemei, LI Yan,
Cancer Research on Prevention and Treatment. 2022, 49 (03): 246-250.   DOI: 10.3971/j.issn.1000-8578.2022.21.0445
Abstract( 132 PDF (8444KB)  ( 78 ) )   HTML ()
Standardization for Diagnosis and Treatment of Primary Hepatic Carcinoma (2022 Edition)
National Health Commission of the People's Republic of China
Cancer Research on Prevention and Treatment. 2022, 49 (03): 251-276.   DOI: 10.3971/j.issn.1000-8578.2022.03.0001
Abstract( 306 PDF (4752KB)  ( 85 ) )   HTML ()
15 articles